Biogen-Funded Collaboration with Americares and Harvard Chan C-CHANGE Recognized by the Clinton Global Initiative


Northampton, MA – News Direct – Biogen

Americares President and CEO Christine Squires shakes hands with Chelsea Clinton on stage at the 2022 Clinton Global Initiative meeting in New York City.  Photo by Yael Gottlieb for Americares.

Americares President and CEO Christine Squires shakes hands with Chelsea Clinton on stage at the 2022 Clinton Global Initiative meeting in New York City. Photo by Yael Gottlieb for Americares.

Across the United States, the climate crisis is threatening the ability of thousands of community health centers to care for millions of uninsured or underinsured patients. To address climate-related risks to their operations and patient health, Biogen is collaborating with Americares and the Center for Climate, Health, and the Global Environment at Harvard TH Chan School of Public Health (Harvard Chan C-CHANGE). This week, the Clinton Global Initiative recognized the commitment made through this partnership and the global expansion of the program with the Harvard Global Health Institute.

Also Read :  Aleph Farms Expands Global Leadership Team with Key Appointment and New Office in the United States

Together, the organizations are creating a unique toolkit for climate-resilient healthcare clinics that will help clinics leverage available resources to better manage patient care as they face increasingly common climate health impacts. A toolkit module on extreme heat has already been rolled out in pilot clinics. Wildfire and Hurricane modules will follow later this year.

Biogen’s support for the program is part of this Healthy climate, healthy life™ Initiative, the company’s groundbreaking 20-year, $250 million initiative to fight climate, health and justice. The commitment aims to eliminate fossil fuel emissions from all operations by 2040, engage employees and suppliers, and work with renowned institutions to advance science and action to improve health outcomes.

Also Read :  Stater Bros. CEO Pete Van Helden adds chairman’s title

About BiogenAs pioneers in neuroscience, Biogen discovers, develops and commercializes innovative therapies worldwide for people living with serious neurological disorders and related therapeutic contexts. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Sir Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has a leading portfolio of drugs to treat multiple sclerosis, introduced the first approved treatment for spinal muscular atrophy, and developed the first and only approved treatment to treat a specific pathology of Alzheimer’s disease. Biogen also commercializes biosimilars and is focused on advancing one of the industry’s most diversified neuroscience pipelines that will transform the standard of care for patients in several areas of high unmet need.

Also Read :  Public schools face shortages as thousands of K-12 staffers quit during back-to-school season

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – TwitterLinkedIn, Facebook, YouTube.

Check out additional multimedia content and more ESG storytelling from Biogen at 3blmedia.com

View the source version on newsdirect.com: https://newsdirect.com/news/biogen-funded-collaboration-with-americares-and-harvard-chan-c-change-recognized-by-the-clinton-global -initiative- 907107179





Source link